Exhibit booth will highlight solutions that offer new ways to address today’s most critical lab challenges and deliver better patient care.
INDIANAPOLIS and CHICAGO, July 22, 2022 /PRNewswire/ --Roche (SIX: RO,ROG) (OTCQX: RHHBY) will showcase a cutting-edge interactive and solutions-focused exhibit at the 2022 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 24-28 in Chicago.
The Roche exhibit booth (No. 2002) will feature the latest solutions that can connect laboratory systems, analyze data and drive new efficiencies so labs have more time to focus on delivering better patient care. To address current laboratory challenges, Roche will also introduce the Roche Idea Lab, where experts in areas critical to laboratory success will provide key insights. These areas include a lab’s success in health equity and testing access, staffing pressures, data optimization, and improving clinical outcomes for patients with cardiometabolic, neurodegenerative and infectious diseases. “Laboratorians want to focus on the tasks that matter most, providing life-impacting results. There is a critical need for solutions that ease staffing pressures and improve testing capacity and access,” said Matt Sause, president and CEO of Roche Diagnostics North America. “Addressing these challenges together is essential to providing patient care, and we are excited that the Roche booth will showcase innovative and integrated solutions that address these needs.” The Roche exhibit booth will feature demonstrations of 18 innovative systems including:
*Product not available for sale in the U.S. A 510(k) submission is pending with the Food and Drug Administration. Roche will also present 11 interactive workshops as part of the Idea Lab to share best practices and provide answers on topics that matter most in today’s evolving lab environment. For more information about Roche’s participation at 2022 AACC and the Idea Lab Program, visit AACC.roche.com. Participation this year is both virtual and in-person. Featured sessions include: Tuesday, July 26 Apprenticeship programs to help address staffing shortages | 10:00 - 10:30 a.m. CDT Navify’s digital ecosystems: The future of healthcare | 10:45 - 11:15 a.m. CDT The sugary slope of type II diabetes to heart failure | 11:30 a.m. - 12:30 p.m. CDT Inclusive by design: How the lab can drive health equity and access | 1:00 - 1:45 p.m. CDT Successful change happens with people | 2:15 - 2:45 p.m. CDT Antimicrobial stewardship in the emergency department | 3:00 - 3:45 p.m. CDT Wednesday, July 27 A unique approach to training to help address staffing shortages | 10:00 - 10:30 a.m. CDT Insights and impact of home testing and self-collection | 11:30 a.m. - 12:30 p.m. CDT Structure, strategy and people: How Roche Healthcare Consulting helps optimize your testing menu | 1:00 - 1:30 p.m. CDT Optimize workflow and staff with cobas® infinity | 2:00 - 2:30 p.m. CDT Automation: Solutions for now, vision for the future | 2:00 - 2:30 p.m. CDT About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalized healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than 30 medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognized as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly-owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. The cobas® pulse and the cobas® pure are in development and are not available for sale in the US. Roche Diagnostics U.S. Media Relations Onsite: Offsite:
SOURCE Roche | ||
Company Codes: OTC-BB:RHHBY, OTC-PINK:RHHBY |
View original content to download multimedia:
